Nimotop ^*

Nimotop is used to prevent brain damage after a specific type of stroke known as an aneurysmal subarachnoid hemorrhage. It works by relaxing the brain's blood vessels to prevent them from narrowing, which maintains blood flow and helps improve neurological recovery. This medication is critical in the weeks following the initial bleed to reduce the risk of secondary complications and long-term injury.

Nimotop should be taken exactly as your healthcare provider instructs, typically on an empty stomach. This means taking your dose at least one hour before or two hours after eating a meal. Swallow the tablet whole with a glass of water. Do not crush or chew the tablets. Consistency is important for the medication to be effective, so try to take your doses at the same times each day.

Nimotop should not be taken with grapefruit or grapefruit juice because it can cause a significant interaction. Grapefruit contains compounds that block an enzyme (CYP3A4) in your intestines and liver. This increases the amount of nimodipine absorbed into your bloodstream, leading to dangerously high drug levels. This can greatly increase your risk of severe side effects, especially a sharp drop in blood pressure.

Nimotop may cause side effects, with the most common ones being related to its effect on blood vessels. These include low blood pressure (hypotension), which can cause dizziness and lightheadedness. Other frequently reported side effects are headache, flushing or a feeling of warmth, nausea, and swelling in the feet or ankles. Most people tolerate the medication well, but you should contact your doctor if these symptoms persist.

Nimotop can lower blood pressure, and alcohol can amplify this effect, potentially leading to increased dizziness, lightheadedness, or fainting. It is generally recommended to limit or avoid alcohol consumption while you are taking this medication. Always discuss your alcohol use with your doctor to understand the specific risks and to receive personalized advice based on your health condition and treatment plan.

If you miss a dose of Nimotop, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, you should skip the missed dose and resume your regular dosing schedule. Do not take a double dose to make up for the one you missed, as this could increase your risk of experiencing side effects like low blood pressure.

Nimotop should be stored in its original packaging at room temperature, between 59-86°F (15-30°C). It is important to protect the medication from both light and moisture to maintain its stability and effectiveness. Keep the bottle tightly closed and store it in a dry place away from the bathroom. As with all medications, keep Nimotop out of the reach of children and pets.

Nimotop is not a blood thinner, also known as an anticoagulant or antiplatelet drug. Instead, Nimotop is a calcium channel blocker that works as a vasodilator. It relaxes and widens the blood vessels, particularly in the brain, to improve blood flow. It does not affect the blood's ability to clot. It is often used alongside other medications after a brain hemorrhage.

Nimotop can cause low blood pressure (hypotension) as a primary side effect, because its main function is to relax blood vessels. Your doctor will monitor your blood pressure while you are on this medication. Symptoms of low blood pressure include dizziness, fainting, or lightheadedness. It is important to stand up slowly from a sitting or lying position to minimize these effects.

The duration of Nimotop treatment is typically very specific and determined by your doctor based on your condition. For subarachnoid hemorrhage, a standard course often lasts for about 21 days after the event. It is crucial to complete the full course of treatment as prescribed, even if you feel better, to ensure you get the maximum protection against vasospasm and potential brain damage.

You should not stop taking Nimotop suddenly without consulting your healthcare provider. Stopping the medication abruptly could lead to a rebound narrowing of the blood vessels in your brain, increasing the risk of the very complications it is meant to prevent. Your doctor will provide instructions on how to safely complete your course of treatment. Always follow the prescribed duration.

Nimotop is not approved for the routine prevention or treatment of migraines. Although some other calcium channel blockers are used for migraine prophylaxis, nimodipine's effects are more selective for the blood vessels in the brain. There have been some small studies, but its role in migraine therapy is not well-established. You should consult a doctor for appropriate migraine treatments.